Healthcare / Drug Manufacturers - Specialty & GenericNSE
$7.00
-0.03 (-0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $7.0M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$913M
P/E
116.7x
↑EV/EBITDA
27.0x
↑ROE
1.3%
↑Gross Margin
12.5%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.0%
FCF CAGR
—
FCF margin
-18.7%
FCF / Net income
-22.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $978.8M · net income $8.2M · FCF $-183.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $978.8M | $978.8M | $817.6M | $638.2M | $715.4M |
| Net Income | $8.2M | $8.2M | $7.2M | $66.0M | $40.2M |
| EBITDA | $37.8M | $37.8M | $37.0M | $116.1M | $86.7M |
| EPS | — | — | 0.07 | 0.59 | 0.38 |
| Gross Margin | 12.5% | 12.5% | 9.0% | 14.3% | 11.2% |
| Operating Margin | 6.0% | 6.0% | 7.8% | 14.1% | 9.1% |
| Net Margin | 0.8% | 0.8% | 0.9% | 10.3% | 5.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.31 | 0.36 | 0.79 |
| Cash Flow | |||||
| Free Cash Flow | $-183.4M | $-183.4M | $7.0M | $7.8M | $4.5M |
| Returns | |||||
| ROE | 1.3% | 1.3% | 1.7% | 16.3% | 15.3% |
| Valuation | |||||
| P/E | 116.67 | 116.67 | 237.79 | 24.53 | 22.47 |
| EV/EBITDA | 26.97 | 26.97 | 51.46 | 14.39 | 12.70 |
| P/B | 1.41 | 1.41 | 4.16 | 3.77 | 3.44 |
| Growth & Yield | |||||
| Revenue Growth | 19.7% | 19.7% | 28.1% | -10.8% | — |
| EPS Growth | — | — | -88.2% | 54.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → n/d
Residual
-46.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.